HK Stock Market Move | GENSCRIPT BIO (01548) is now up more than 6%. Second quarter CARVYKTI sales increased by about 1.36 times year-on-year.

GENSCRIPT BIO (01548) is now up over 6%, as of press time, up 5.07% to 16.16 Hong Kong dollars, with a turnover of 434 million Hong Kong dollars. On the news front, GENSCRIPT BIO announced that its affiliate Legend Biotech disclosed that CARVYKTI's trade sales net revenue for the second quarter ended June 30 was approximately 439 million US dollars, an increase of about 1.36 times compared to the same period last year when trade sales net revenue was approximately 186 million US dollars. The group stated that the trade sales net revenue is based on information provided by Johnson & Johnson to Legend Biotech, and both Legend Biotech and the group have not independently verified the accuracy of these sales figures. It is worth noting that GENSCRIPT BIO announced at the end of last month that its subsidiary Pongbo received approximately 214 million US dollars from BeiGene. The payment includes the following: upfront payment; milestone payment for achieving the first milestone; and sublicense income related to the anti-PD-1 single-domain antibody licensed under the restated and amended license agreement. The anti-PD-1 single-domain antibody is used in BeiGene's investigational PD1/VEGF bispecific antibody LM-299, which has received regulatory approval for clinical trials.